Physician profile
Mitzi C Brock
NPI 1417956970
$2,300.39
in general payments reported to CMS, 2019-2025
33 companies · $501 in 2025
The $501 reported for 2025 was more than what 75% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $201 · 2021: $131 · 2022: $587 · 2023: $380 · 2024: $268 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134 · Gift: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.00 |
| Gift | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $386.67 | 2019-2025 | |
| Hologic Sales and Service, LLC | $187.19 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $137.57 | 2019-2022 | |
| Pfizer INC. | $117.13 | 2019-2024 | |
| Millicent US INC | $115.73 | 2020-2025 | Intrarosa, Femlyv, Femring |
| Lilly USA, LLC | $112.89 | 2024-2025 | Zepbound |
| Exact Sciences Corporation | $103.31 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mayne Pharma Commercial LLC | $102.32 | 2021-2025 | |
| Astellas Pharma US INC | $95.80 | 2021-2025 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $93.15 | 2022-2024 | Accrufer |
| Abbvie INC. | $76.45 | 2019-2025 | |
| Radius Health, INC. | $72.05 | 2022-2023 | |
| Organon LLC | $68.91 | 2022-2025 | Jada System, Nexplanon |
| Sumitomo Pharma America, INC. | $68.08 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $59.31 | 2021-2025 | Slynd |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $53.29 | 2022-2023 | Saffron |
| Scynexis, INC. | $44.52 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.46 | 2019-2023 | Xifaxan |
| Coopersurgical, INC. | $37.78 | 2022 | |
| Ascend Therapeutics US, LLC | $34.85 | 2021-2024 | |
| Endo Pharmaceuticals INC. | $34.34 | 2020-2022 | |
| Covidien LP | $33.82 | 2019-2020 | |
| Novo Nordisk INC | $33.70 | 2025 | |
| Galderma Laboratories, L.P. | $32.31 | 2025 | |
| Minerva Surgical, INC | $26.26 | 2022-2023 | |
| Pacira Pharmaceuticals Incorporated | $23.44 | 2023 | Exparel |
| Allergan, INC. | $23.27 | 2019 | |
| Lsi Solutions INC | $22.84 | 2024 | Fornisee |
| Duchesnay USA Incorporated | $17.61 | 2019 | |
| Lupin INC. | $17.52 | 2020 | |
| Myovant Sciences INC. | $14.39 | 2022 | |
| Amgen INC. | $12.43 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitzi Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.